20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
07:00 , Oct 20, 2016 |  BC Innovations  |  Finance

3Q16 Public-Private Partnership Roundup

  Formation of new PPPs cooled off considerably this summer after a blistering pace in 2Q16, with the fewest preclinical research-oriented partnerships since 3Q14. Only 37 partnerships were recorded by BioCentury in 3Q16, a nearly...
07:00 , Sep 25, 2014 |  BC Innovations  |  Strategy

Canadian accelerant

After seven years of building bridges between the Canadian research and business communities through technology transfer consortia, the government's Centres of Excellence for Commercialization and Research program has launched the country's first national health science...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Accel-Rx Health Sciences Accelerator finance news

Accel-Rx, a pan-Canadian health sciences accelerator, announced its official launch after receiving a C$14.5 million ($13.1 million) award from the Canadian government's Centers of Excellence for Commercialization and Research (CECR) program. CDRD Ventures Inc. ,...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Tekmira management update

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C.   Business: Cancer, Drug delivery   Transitioned: Michael Abrams as EVP and chief discovery officer from an independent director, formerly chief innovation officer and VP of R&D of...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Kairos Therapeutics, Centre for Drug Research and Development cancer news

Centre for Drug Research and Development’s (CDRD) commercialization vehicle, CDRD Ventures Inc. , spun off Kairos to develop next-generation antibody-drug conjugate (ADC) therapeutics for cancer. CDRD Ventures granted Kairos an exclusive license to toxin and...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Sitka Biopharma, Centre for Drug Research and Development, University of British Columbia cancer news

CDRD Ventures Inc. , the commercialization vehicle for the non-profit Centre for Drug Research and Development, launched cancer company Sitka Biopharma. Sitka's lead candidate consists of docetaxel administered intravesically into the bladder via the company's...
07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Trapping influenza neuraminidase

Researchers at The University of British Columbia have used a mechanism-based approach to design irreversible inhibitors of influenza virus neuraminidase that could have activity against flu strains resistant to marketed inhibitors of the target. 1...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Influenza virus neuraminidase In vitro, cell culture and mouse studies suggest covalent neuraminidase inhibitors could be useful for treating influenza infection. In...
07:00 , Jun 21, 2012 |  BC Innovations  |  Strategy

GSK completes its Canadian tripod

GlaxoSmithKline plc and the not-for-profit Centre for Drug Research and Development have partnered to fund research from academic institutions across Canada. The deal completes a trio of alliances established by the pharma in the last...